CRISPR moves beyond rare blood diseases: first-of-its-kind human trial safely targets a cholesterol-regulating gene
CRISPR moves beyond rare blood diseases: first-of-its-kind human trial safely targets a cholesterol-regulating gene
CRISPR just reached a new milestone in human medicine. For the first time, scientists have safely used gene editing to turn off a cholesterol-regulating gene in peopleβa step that moves the technology beyond rare genetic disorders toward treating common diseases like heart disease.
π― Phase 1 Trial Marks First Human Test of CRISPR on a Cholesterol Gene
The first human trial of CRISPR gene editing for cholesterol just delivered promising results. Researchers tested CTX310, which uses CRISPR to disable the ANGPTL3 gene in the liver (this gene normally blocks enzymes that break down cholesterol).
15 participants with stubborn high cholesterol got a single IV dose, with the highest doses reducing ANGPTL3 protein levels by 73-80%
No serious side effects were linked to the treatment - one person died 179 days later from an unrelated sudden death, and another had a spinal disk issue
Only mild reactions occurred: 3 people (20%) had infusion reactions, and 1 person had temporary liver enzyme elevation that resolved in 2 weeks
Why it matters: For the first time, CRISPR has been used to safely switch off a cholesterol-raising gene in humansβa step beyond treating rare genetic diseases. The approach mimics naturally protective mutations that keep cholesterol and triglycerides low, hinting at a future where heart disease prevention could come from a one-time edit, not daily pills.
Key Findings
𧬠Magnetic Nanorobots Boost Gene Editing Efficiency
Scientists created tiny magnetic robots (200 nanometers) that can actively move CRISPR components through cells. These "MagCbots" spin at high speeds when exposed to magnetic fields, reaching velocities of 0.41 micrometers per second inside cells. The spinning motion reduced cellular thickness by 50% and tripled the escape rate from cellular compartments that normally trap and destroy genetic material.
π¬ Prime Editing Fixes Heart Disease Mutation
Researchers used prime editing (a newer, more precise form of gene editing) to correct a heart muscle disease mutation in human heart cells grown from stem cells. They achieved 34.8% editing efficiency in correcting the RBM20-P633L mutation that causes dilated cardiomyopathy. The editing restored normal protein location and fixed abnormal splicing of heart-related genes.
π― New RNA Editing System Lowers Cholesterol in Mice
Scientists developed "ProAPOBECs" - enhanced RNA editing tools that can modify genetic messages without permanently changing DNA. When they used these tools to edit Pcsk9 RNA in mouse livers (a gene that regulates cholesterol), it effectively lowered cholesterol levels. They also tested it in an autism mouse model, where editing Mef2c RNA significantly improved disease symptoms.
π§ͺ Anti-CRISPR Proteins Enable Precise Control
Researchers solved a major CRISPR problem in bacteria by combining the gene editing system with "anti-CRISPR" proteins that can turn it on and off. Using the AcrIIA4 protein from Listeria, they successfully edited genes in the notoriously difficult-to-modify bacterium Clostridium beijerinckii. The system allowed multiple rounds of editing while preventing the toxicity that usually kills bacterial cells during CRISPR experiments.
π¬ CRISPR Targets Cancer's Fusion Genes
Scientists used CRISPR to disrupt BRD4::NUTM1, an abnormal fusion gene that drives NUT carcinoma, a highly aggressive cancer with no established treatments. Multiple guide RNAs successfully broke apart the fusion gene at the DNA level, eliminating the cancer-driving protein. This led to significant reductions in cancer cell growth, cell cycle arrest, and increased cell death.
π Eleven Testis Genes Prove Unnecessary for Male Fertility
Two separate studies knocked out 17 different genes that are highly active in testicles to see which ones are essential for male fertility. Surprisingly, mice lacking any of these 17 genes maintained completely normal fertility, testis appearance, sperm quality, and reproductive success in mating tests. This included genes like Efcab7, Tekt3, and others previously thought to be important for reproduction.
Implications
This week's research shows CRISPR moving from lab curiosity to real medical treatments, with the first human cholesterol trial proving safety and efficacy. Meanwhile, new delivery methods and control systems are solving the technical challenges that have limited gene editing's reach, potentially opening doors to treating everything from muscle diseases to cancer.
Studies in this issue
Primary sources used for this newsletter.
- Early Human Trial of Gene Editing Targeting ANGPTL3main storyThe New England journal of medicine2025-11-10PMID 41211945
- Magnetic fast-moving tiny particle groups to improve CRISPR/Cas9 gene editingkey findingACS applied materials & interfaces2025-11-04PMID 41185939
- Editing genes shows 10 testis-specific and 1 other gene are not needed for male fertility in micekey findingAndrology2025-11-10PMID 41208519
- Efficient RNA base editing in living cells using engineered enzymes combining cytidine deaminase and RNA-binding proteinskey findingNature communications2025-11-04PMID 41188225
- Prime editing fixes heart muscle disease caused by RBM20-P633L mutation in human heart cellskey findingMolecular therapy. Nucleic acids2025-11-10PMID 41210585
- Using CRISPR-Cas9 gene editing to target cancer caused by fusion genes in NUT carcinomakey findingMolecular therapy. Oncology2025-11-05PMID 41190236
- Using CRISPR and anti-CRISPR tools to edit the DNA of Clostridium beijerinckii bacteriakey findingJournal of biotechnology2025-11-07PMID 41202983
Continue reading
All CRISPR Gene Editing issuesGet the next CRISPR Gene Editing issue
Seven papers, once a week. Free.